Article Type
Original Research
Published
In this real-life study, the authors aim to evaluate the prognostic role of variations in cancer antigen 15.3 (CA15.3) and carcinoembryonic antigen (CEA) levels in patients with HR+/HER2− breast cancer treated with CDK4/6 inhibitors. The goal of this investigation is to consider whether it would be possible to use these markers as a monitoring tool to diagnose earlier, faster and in a more practical way.
